Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 300

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 300
---
 the registration statement. Some items are contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our securities, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or document referred to are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. In addition, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public on a website maintained by the SEC located at www.sec.gov.We also maintain a website at www.cero.bio/investors.Through our website, we make available, free of charge, annual, quarterly and current reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into, this prospectus. Information contained on our website is not a part of or incorporated by reference into this prospectus and the inclusion of our website and investor relations website addresses in this prospectus is an inactive textual reference only. 173 INDEX TO FINANCIAL STATEMENTS CERO THERAPEUTICS HOLDINGS, INC. Unaudited Financial Statements as of March 31, 2025 and December 31, 2024

| Condensed                                                                                                                                   
 Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024                                                                      
 Condensed                                                                                                                                   
 Consolidated Statements of Operations for the Three Months Ended March 31, 2025 (Successor), Period from February 14, 2024 through          
 March 31, 2024 (Successor),  and January 1, 2024 through February 13, 2024 (Predecessor)                                                    |     | F-2        
 F-3        |
|:--------------------------------------------------------------------------------------------------------------------------------------------|:----|:-----------|
| Condensed                                                                                                                                   
 Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit for the three months ended March 31, 2025                  
 (Successor), Periods from February 14,